113 related articles for article (PubMed ID: 2592819)
1. [Preventive effect of urinastatin on cisplatin-induced nephrotoxicity].
Kobayashi H; Ishizuka H; Hirashima Y; Ohi H; Demukai H; Moniwa M; Maeda M; Kobayashi T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1959-64. PubMed ID: 2592819
[TBL] [Abstract][Full Text] [Related]
2. [Effects of urinastatin against nephrotoxicity of cisplatinum].
Arakawa A; Kato N; Asai H; Yasui Y; Suzumori K; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2229-34. PubMed ID: 2241187
[TBL] [Abstract][Full Text] [Related]
3. [Preventive effect of urinastatin on cisplatin induced nephrotoxicity in rabbits].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Mar; 41(3):328-32. PubMed ID: 2567322
[TBL] [Abstract][Full Text] [Related]
4. [Cisplatin and ovarian carcinoma--early detection of cisplatin-induced nephrotoxicity].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):888-96. PubMed ID: 4040542
[TBL] [Abstract][Full Text] [Related]
5. [Prophylactic effect of ulinastatin on cisplatin-induced renal disorders in lung cancer patients].
Horiguchi T; Kasahara J; Ogura K; Handa M; Hosoda H; Shakato A; Tachikawa S; Sato M; Suetsugu S; Umeda H
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Jan; 30(1):12-9. PubMed ID: 1625386
[TBL] [Abstract][Full Text] [Related]
6. [The study of cyclic maintenance chemotherapy with cisplatin, adriamycin, and cyclophosphamide (cyclic PAC chemotherapy) in patients with advanced ovarian cancer].
Kobayashi H; Hayata T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1936-42. PubMed ID: 2592816
[TBL] [Abstract][Full Text] [Related]
7. [Effects of urinastatin on prevention of cisplatin induced nephrotoxicity].
Sasa H; Hisano A; Kudo K; Kuki E; Miyauchi M; Kita T; Kikuchi Y; Tode T; Furuya K; Nagata I
Gan To Kagaku Ryoho; 1991 Dec; 18(15):2623-5. PubMed ID: 1746976
[No Abstract] [Full Text] [Related]
8. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
Kubota A; Yoshida T; Tsukuda M; Furukawa S; Miyata K; Mochimatsu I; Sawaki S
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2599-605. PubMed ID: 2774590
[TBL] [Abstract][Full Text] [Related]
9. [Prevention of cisplatin induced nephrotoxicity by administering urinastatin to rabbits--comparison with other protease inhibitors].
Kobayashi H; Ohi H; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jun; 41(6):683-7. PubMed ID: 2475558
[TBL] [Abstract][Full Text] [Related]
10. [Cyclic high dose CAP therapy by short-stay admission for ovarian malignancies--to increase total dose of CDDP and to improve quality of life of patients].
Ochiai K; Isonishi S; Kimura E; Yokoyama S; Sasaki H; Arihiro T; Terashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jan; 43(1):19-25. PubMed ID: 1997612
[TBL] [Abstract][Full Text] [Related]
11. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
[TBL] [Abstract][Full Text] [Related]
12. [A clinical evaluation of the protective effect of fosfomycin (FOM) against the cis-diamminedichloroplatinum (CDDP)-induced nephrotoxicity].
Saito M; Masaki T; Kato H; Numasaka K
Hinyokika Kiyo; 1988 May; 34(5):782-9. PubMed ID: 3051938
[TBL] [Abstract][Full Text] [Related]
13. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
14. [Determination of urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion as a parameter of nephrotoxicity due to cis-platin and the effect of fosfomycin (FOM) on its nephrotoxicity].
Matsuoka R; Inoue T; Miyamura K; Mizutani K; Koike S; Mori H; Kigawa T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Nov; 38(11):2037-44. PubMed ID: 3794453
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
Conte PF; Bruzzone M; Carnino F; Chiara S; Donadio M; Facchini V; Fioretti P; Foglia G; Gadducci A; Gallo L
J Clin Oncol; 1991 Apr; 9(4):658-63. PubMed ID: 2066762
[TBL] [Abstract][Full Text] [Related]
16. [Urinary NAG and gamma-GTP activities as indicators of CDDP renal toxicity: effect of fosfomycin on CDDP renal toxicity].
Yoshida K; Takahashi T; Nakame Y; Saitoh H; Horiuchi S; Kaneoya F; Negishi T
Hinyokika Kiyo; 1986 Sep; 32(9):1237-45. PubMed ID: 2880486
[TBL] [Abstract][Full Text] [Related]
17. [Prophylactic effect of fosfomycin on CDDP nephrotoxicity].
Yogi S; Ikeuchi T; Kai Y
Hinyokika Kiyo; 1989 Apr; 35(4):615-21. PubMed ID: 2735267
[TBL] [Abstract][Full Text] [Related]
18. Urinastatin (Kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity.
Umeki S; Tsukiyama K; Okimoto N; Soejima R
Am J Med Sci; 1989 Oct; 298(4):221-6. PubMed ID: 2552802
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of side effects of a combination chemotherapy of cisplatin and adriamycin in gynecological malignancies: comparison between intravenous and intraarterial administration].
Kawagoe K; Tsunoda H; Iijima S; Yokota H; Shigemitsu S
Gan To Kagaku Ryoho; 1984 Mar; 11(3):452-7. PubMed ID: 6538404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
